<DOC>
	<DOCNO>NCT01471184</DOCNO>
	<brief_summary>The primary objective study assess relative efficacy Ectoin® Allergy Eye Drops Ectoine® Allergy Nasal Spray compare placebo , evaluate Total Nasal Symptom Score ( TNSS ) Total Ocular Symptom Score ( TOSS ) . The secondary objective : - To evaluate relative efficacy Ectoin® Allergy Eye Drops Ectoin® Allergy Nasal Spray compare placebo evaluate Total Non Nasal Symptom Score ( TNNSS ) , congestion symptom score , red eye symptom score , watery eye symptom score , itchy eye symptom score , evaluate mean cross-sectional area ( MCA ) use acoustic rhinometry ( AcR ) . - To assess change baseline ( post-EEC pre-EEC ) inflammatory parameter nasal secretion , compare Ectoin® Allergy Eye Drops Ectoin® Allergy Nasal Spray placebo post-treatment visit .</brief_summary>
	<brief_title>The Effects Ectoin® Allergy Nasal Spray Ectoin® Allergy Eye Drops Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Patients must clinical history SAR seasonal onset offset nasal ocular allergy symptom least last two ragweed allergy season . 2 . Adults ( male female ) age 18 65 , inclusive . 3 . Patients must documentation positive skin test within 12 month screen ragweed positive skin prick and/or intradermal test ragweed allergen Visit 1 . A positive response define wheal diameter least 3 mm large negative control skin prick test least 7 mm large negative control intradermal test . 4 . Nonpregnant , nonlactating woman childbearing potential postmenopausal [ define least 6 month natural spontaneous amenorrhea ] , surgically sterile ( hysterectomy ; bilateral oophorectomy ; bilateral tubal ligation surgery least 6 week prior study initiation ) . Surgical sterility support clinical documentation . Females must confirm absence pregnancy accord negative serum pregnancy test urine pregnancy test time describe Section 11 . Female subject child bear potential must agree use reliable highly effective method birth control low failure rate ( i.e . le 1 % per year ) use consistently correctly ( e.g . implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner ) trial , judge investigator . For subject use hormonal contraceptive method , information regard product evaluation potential effect contraceptive address . 5 . In generally good health basis medical history physical examination . 6 . Willingness attend study visit . 7 . Capable follow understanding instruction . 8 . Willing able provide write informed consent prior initiation study procedure , include initiation washout concomitant medication . 1 . Asthma base medical history investigator judgment ( stable mild asthmatic may include ) . 2 . Current smoker exsmokers 10 pack year smoke history . One pack year define 20 cigarettes/day 1 year . Smoking must stop 6 month ago 3 . History low upper airway infection last four week prior screen . 4 . Clinically significant physical finding nasal anatomical deformity cause great 50 % obstruction base clinical estimate investigator , include nasal polyp , septal defect clinically significant respiratory tract malformation , nasal piercing , recent nasal biopsy , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa within 60 day prior Screening Visit . 5 . Pregnancy breastfeeding , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period , 30 day follow study period . 6 . Currently participate clinical trial expose investigational treatment within 30 day prior Screening Visit . 7 . A know suspected hypersensitivity , and/or contraindication ingredient investigational product . 8 . History alcohol drug abuse , judge investigator , within two year prior Screening Visit . 9 . Use prohibit medication within identify exclusion period ( see Section 3.2.4 ) 10 . Any acute chronic disease , opinion investigator , would affect study objective subject safety ( e.g. , Diabetes mellitus type I , malignant neoplasia , chronic renal failure , inflammatory disease liver kidney , emphysema , bronchiectasis ) . 11 . Any clinically significant ( determined investigator ) psychiatric and/or psychological disorder , include impairment cooperation ( e.g . alcohol drug abuse ) . 12 . Patients able follow study procedure ( e.g . language problem , psychological disorder ) . 13 . Suspected noncompliance study protocol . Noncompliance e.g . application le 60 % ( accord post treatment container 's weight ) miss one application either last two day EEC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Conjunctivitis</keyword>
	<keyword>Bitop</keyword>
	<keyword>Eye</keyword>
	<keyword>Eye Drops</keyword>
	<keyword>Nasal Spray</keyword>
	<keyword>Total Nasal Symptom Score</keyword>
	<keyword>Total Ocular Symptom Score</keyword>
	<keyword>AUC</keyword>
</DOC>